Oxidative stress and generation of reactive oxygen species are believed to be implicated in Parkinson’s disease (PD). Erythrocyte activity of superoxide dismutase (SOD) and catalase, the blood glutathione system, and plasma levels of thiobarbituric-acid-reactive substances (TBARS) were measured in 80 PD patients. These biochemical parameters were also measured in 29 age-matched controls. Patients with PD had significantly higher red blood corpuscle (RBC) activity of SOD. The mean RBC activity of catalase in PD patients did not differ significantly from those of controls. RBC catalase activity was significantly lower in advanced cases of PD compared to early cases. Oxidized glutathione was significantly higher in RBCs of PD patients, although there were no changes in total glutathione and reduced glutathione compared to controls. TBARS content was increased in patients with PD. Levodopa therapy, age and duration of illness did not significantly influence the measured parameters. Our study supports the previous hypothesis that oxidative stress is implicated in the pathogenesis of PD. Perspectives for treatment of PD in the future could include antioxidant therapy.

Keywords:
Parkinson’s disease, Oxidative stress, Superoxide dismutase, Catalase, Glutathione, Malondialdehyde
1.
Floyd RA, Carney JM: Free radical damage to protein and DNA: mechanisms involved and relevant observations on brain undergoing oxidative stress. Ann Neurol 1992;32:S22–S27.
2.
Floyd RA, Zaleska M, Harmon HJ: Possible involvement of iron in oxygen free radicals in aspects of aging in brain; in Armstrong D, et al (eds): Free Radicals in Molecular Biology: Aging and Disease. New York, Raven Press, 1984, pp 143–161.
3.
Dexter DT, Wells FR, Agid F, et al: Increased nigral iron content in post-mortem parkinsonian brain. Lancet 1987;ii:1219–1220.
4.
Olanow CW: Oxidation reactions in Parkinson’s disease. Neurology 1990;40:32–37.
5.
Graham DG: Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinines. Mol Pharmacol 1978;14:633–643.
6.
Cohen G: The pathobiology of Parkinson’s disease: biochemical aspects of dopamine neuron senescence. J Neural Transm 1983;19(suppl):89–103.
7.
Perry TL, Godin DV, Hansen S: Parkinson’s disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 1982;33:305–310.
8.
Sian J, Dexter DT, Lees AJ, et al: Alteration in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 1994;36:348–355.
9.
Jenner P, Olanow CW: Understanding cell death in Parkinson’s disease. Ann Neurol 1998;44:72–84.
10.
Ambani LM, Van Woert MH, Murphy S: Brain peroxidase and catalase in Parkinson’s disease. Arch Neurol 1975;32:114–118.
11.
Good PF, Hsu A, Werner P, Perl DP, Olanow CW: Protein nitration in Parkinson’s disease. J Neuropathol Exp Neurol 1998;57:338–342.
12.
Sanchez-Ramos J, Overvik E, Ames BA: Marker of oxyradical-mediated DNA damage (8-hydroxy-2′-deoxyguanosine) is increased in nigrostriatum of Parkinson’s disease brains. Neurodegeneration 1994;3:197–204.
13.
Dexter DT, Carter CJ, Wells FR, et al: Basal lipid peroxidation in substantia nigra increased in Parkinson’s disease. J Neurochem 1989;52:381–389.
14.
Dexter DT, Holley AE, Flitter WD, et al: Increased levels of lipid hydroperoxides in parkinsonian substantia nigra: an HPLC and ESR study. Mov Disord 1994;9:92–97.
15.
Parker WD Jr, Boyson SJ, Parks JK: Abnormalities of the electron transport chain in idiopathic Parkinson’s disease. Ann Neurol 1989;26:719–723.
16.
Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD: Mitochondrial complex I deficiency in Parkinson’s disease. J Neurochem 1990;54:823–827.
17.
Schapira AH, Mann VM, Cooper JM, Krige D, Jenner P, Marsden CD: Mitochondrial function in Parkinson’s disease. The Royal Kings and Queens Parkinson’s Disease Research Group. Ann Neurol 1992;32:S116–S124.
18.
Hughes AJ, Ben-Shlomo SE, Daniel SE, Lees AJ: What features improve the accuracy of clinical diagnosis in Parkinson’s disease: a clinicopathological study. Neurology 1992;2:1142–1146.
19.
Hoehn MM, Yahr MD: Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427–442.
20.
Marklund S, Marklund G: Involvement of the superoxide anion radical in the autoxidation of pyrogallol and an inconvenient assay for superoxide dismutase. Eur J Biochem 1974;47:469–474.
21.
Beers B, Sizer WA: Spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase. J Biol Chem 1952;195:133–139.
22.
Akerboom TP, Sies DH: Assay of glutathione, glutathione disulfide and glutathione mixed disulfides in biological samples; in Jakoly W (ed): Detoxification and Drug Metabolism: Conjugation and Related Systems. Methods Enzymol. London, Academic Press, 1981, vol 77, pp 373–382.
23.
Richard MJ, Arnaud J, Jurkovitz C, et al: Trace elements and lipid peroxidation abnormalities in patients with chronic renal failure. Nephron 1991;57:10–15.
24.
Kalra J, Rajput AH, Mantha SV, Prasad K: Serum antioxidant enzyme activity in Parkinson’s disease. Mol Cell Biochem 1992;110:165–168.
25.
Ilic Tihomir V, Jovanovic M, Jovicic A, et al: Oxidative stress indicators are elevated in de novo Parkinson’s disease patients. Funct Neurol 1999;14:141–147.
26.
Kocatürk PA, Akbostanci MC, Tan F, Kavas GÖ: Superoxide dismutase activity and zinc and copper concentrations in Parkinson’s disease. Pathophysiology 2000;7:63–67.
27.
Serra JA, Dominguez RO, De Lustig ES, et al: Parkinson’s disease is associated with oxidative stress: comparison of peripheral antioxidant profiles in living Parkinson’s, Alzheimer’s and vascular dementia patients. J Neural Transm 2001;108:1135–1148.
28.
De la Torre R, Casado A, Lopez-Fernandez E, et al: Human aging brain disorders: role of antioxidant enzymes. Neurochem Res 1996;21:885–888.
29.
Bostantjopoulou S, Kyriaz G, Katasarou Z, et al: Superoxide dismutase activity in early and advanced Parkinson’s disease. Funct Neurol 1997;12:63–68.
30.
Ihara Y, Chuda M, Kuroda S, Hayabara T: Hydroxyl radical and superoxide dismutase in blood of patients with Parkinson’s disease: relationship to clinical data. J Neurol Sci 1999;170:75–76.
31.
Abraham S, Souandarajan CC, Vivekanandhan S, Behari M: Erythrocyte antioxidant enzymes in Parkinson’s disease. Indian J Med Res 2005;121:111–115.
32.
Sudha K, Rao A, Rao S, Rao A: Free radical toxicity and antioxidants in Parkinson’s disease. Neurol India 2003;51:60–62.
33.
Marttila RJ, Lorentz H, Rinne UK: Oxygen toxicity protecting enzymes in Parkinson’s disease: increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus. J Neurol Sci 1988;86:321–331.
34.
Yoshida E, Mokuno K, Aoki SI: Cerebrospinal fluid levels of superoxide dismutases in neurological diseases detected by sensitive enzyme immunoassays. J Neurol Sci 1994;124:25–31.
35.
Saggu H, Cooksey J, Dexter D et al: A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. Neurochem 1989;53:692–697.
36.
Urakami K, Sano K, Matsushima E, et al: Decreased superoxide dismutase activity in erythrocytes in Parkinson’s disease. Jpn J Psychiatry Neurol 1992;46:933–936.
37.
Kilinc A, Yalcin AS, Yalcin D, Taga Y, Emerk K: Increased erythrocyte susceptibility to lipid peroxidation in human Parkinson’s disease. Neurosci Lett 1988;87:307–310.
38.
Riederer P, Sofic E, Rausch WD, et al: Transition metals, ferritin, glutathione and ascorbic acid in parkinsonian brains. J Neurochem 1989;52:515–520.
39.
Sofic E, Lange KW, Jellinger K, Riederer P: Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson’s disease. Neurosci Lett 1992;142:128–130.
40.
Sagara JI, Miura K, Bannai S: Maintenance of neuronal glutathione by glial cells. J Neurochem 1993;61:1672–1676.
41.
Mytilineou C, Kramer BC, Yabut JA: Glutathione depletion and oxidative stress. Parkinsonism Relat Disord 2002;8:385–387.
42.
Ahlskog JE, Uitti RJ, Low PA, et al: No evidence of systemic oxidant stress in Parkinson’s or Alzheimer’s disease. Mov Disord 1995;10:566–573.
43.
Molina JA, Jimenez-Jimenez FJ, Fernandez-Calle P, et al: Serum lipid peroxides in patients with Parkinson’s disease. Neurosci Lett 1992;136:137–140.
44.
Poirier J, Barbeau A: Erythrocyte antioxidant activity in human patients with Parkinson’s disease. Neurosci Lett 1987;75:345–348.
45.
Agil A, Duran R, Barrero F, Morales B, Arauzo M, Alba F, Miranda M T, Prieto I, Ramirez M, Vives F: Plasma lipid peroxidation in sporadic Parkinson’s disease. role of the L-dopa. J Neurol Sci 2006;240:31–36.
46.
Buhmann C, Arlt S, Kontush A, Möller-Bertram T, Sperber S, Oechsner M, Stuerenburg HJ, Blisiegel U: Plasma and CSF markers of oxidative stress are increased in Parkinson’s disease and influenced by antiparkinsonian medication. Neurobiol Dis 2004;15:160–170.
47.
Perry TL, Yong VW, Ito M, et al: Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-dopa and carbidopa chronically. J Neurochem 1984;43:990–993.
48.
Ahlskog JE, Uitti RJ, Low PA, Tyce GM, O’Brien JF, Nickander KK: Levodopa and deprenyl treatment effects on peripheral indices of oxidant stress in Parkinson’s disease. Neurology 1996;46:796–801.
49.
Martignoni E, Blandini F, Godi L, et al: Peripheral markers of oxidative stress in Parkinson’s disease: the role of L-dopa. Free Radic Biol Med 1999;27:428–437.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.